PE20070194A1 - Compuestos de pirazolina 4-sustituidos como moduladores de cb1 - Google Patents
Compuestos de pirazolina 4-sustituidos como moduladores de cb1Info
- Publication number
- PE20070194A1 PE20070194A1 PE2006000847A PE2006000847A PE20070194A1 PE 20070194 A1 PE20070194 A1 PE 20070194A1 PE 2006000847 A PE2006000847 A PE 2006000847A PE 2006000847 A PE2006000847 A PE 2006000847A PE 20070194 A1 PE20070194 A1 PE 20070194A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydro
- phenyl
- pyrazole
- heteroaryl
- carboxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X ES O, S; R1 Y R2 SON CADA UNO ARILO O HETEROARILO SUSTITUIDO O NO, CONDENSADO CON UN SISTEMA CICLICO MONO O POLICICLICO, CICLOALIFATICO, ENTRE OTROS; R3 ES ARILO O HETEROARILO SUSTITUIDO O NO, RADICAL CICLOALIFATICO MONOSUSTITUIDO, SATURADO O NO, ENTRE OTROS; R4 ES F, Cl, Br, -CN, -NH2, -SH, ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, F, I, -CN, -SH. COOH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE PIPERIDIN-1-ILAMIDA DEL ACIDO CIS-5-(4-CLOROFENIL)-1-(2,4-DICLOROFENIL)-4-METIL-4,5-DIHIDRO-1-H-PIRAZOL-3-CARBOXILICO; AZEPAN-1-ILAMIDA DEL ACIDO TRANS-5-(4-CLORO-FENIL)-1-(2,4-DICLORO-FENIL)-4-METIL-4,5-DIHIDRO-1H-PIRAZOL-3-CARBOXILICO; (2,3-DIHIDRO-INDOL-1-IL)-AMIDA DEL ACIDO TRANS-5-(4-CLORO-FENIL)-1-(2,4-DICLORO-FENIL)-4-METIL-4,5-DIHIDRO-1H-PIRAZOL-3-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES CANNABINOIDES CB1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05384029A EP1743890A1 (en) | 2005-07-15 | 2005-07-15 | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
US70543205P | 2005-08-05 | 2005-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070194A1 true PE20070194A1 (es) | 2007-05-11 |
Family
ID=35429576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000847A PE20070194A1 (es) | 2005-07-15 | 2006-07-14 | Compuestos de pirazolina 4-sustituidos como moduladores de cb1 |
Country Status (13)
Country | Link |
---|---|
US (5) | US20070073056A1 (es) |
EP (6) | EP1743890A1 (es) |
JP (3) | JP2009501181A (es) |
KR (1) | KR20080032157A (es) |
CN (3) | CN101263120A (es) |
AU (1) | AU2006271994A1 (es) |
BR (1) | BRPI0613057A2 (es) |
CA (3) | CA2612468A1 (es) |
MX (3) | MX2008000736A (es) |
PE (1) | PE20070194A1 (es) |
RU (1) | RU2008105761A (es) |
TW (1) | TW200738699A (es) |
WO (5) | WO2007009689A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745476B2 (en) * | 2004-01-30 | 2010-06-29 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1743892A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
KR20100072037A (ko) | 2007-09-20 | 2010-06-29 | 애보트 헬스케어 프로덕츠 비.브이. | 칸나비노이드 cb₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1h)-피라졸 |
EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
US8236821B2 (en) | 2008-05-19 | 2012-08-07 | Jenrin Discovery, Inc. | Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
EP2151234A1 (en) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion |
WO2010079241A1 (es) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
EP2314578A1 (en) * | 2009-10-13 | 2011-04-27 | Esteve Química, S.A. | Cinchonidine salt of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid, useful as intermediate in the preparation of cannabinoid CB1 neutral antagonists |
KR101395658B1 (ko) * | 2012-09-20 | 2014-05-16 | 서울대학교산학협력단 | 4-(5-(2-메톡시페닐)-3-(p-톨릴)-4,5-디하이드로-1H-피라졸-1-일)-4-옥소부탄산을 포함하는 골대사성 질환의 예방 및 치료용 조성물 |
WO2023067518A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | Process |
CN114989040A (zh) * | 2022-07-07 | 2022-09-02 | 南京正荣医药化学有限公司 | 一种吡唑解草酯中间体的合成方法 |
KR102584607B1 (ko) * | 2023-01-19 | 2023-10-04 | 아주대학교산학협력단 | 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 염증성 피부질환 예방 또는 치료용 조성물 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1053661B (it) | 1966-09-27 | 1981-10-10 | Farmacosmici S P A | Ammidi dell acido 3 5 metil 5 3 pirazol carbossilico |
BR8707672A (pt) | 1987-01-05 | 1989-10-03 | Du Pont | Pirazolinas inseticidas |
FR2613720B1 (fr) * | 1987-04-10 | 1990-01-19 | Esteve Labor Dr | Derives d'aryl-heteroaryl carbinols avec activite analgesique |
JPH02117605A (ja) | 1988-10-26 | 1990-05-02 | Nippon Nohyaku Co Ltd | 白蟻防除剤及びその使用方法 |
WO1992003421A2 (en) | 1990-08-17 | 1992-03-05 | E.I. Du Pont De Nemours And Company | Arthropodicidal pyrazolines, pyrazolidines and hydrazines |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2742147B1 (fr) * | 1995-12-06 | 1998-02-27 | Esteve Labor Dr | Procede de separation de carbinols |
AU7966198A (en) * | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
ES2130079B1 (es) * | 1997-07-10 | 2000-01-16 | Esteve Labor Dr | Resolucion de aminas |
ES2130083B1 (es) * | 1997-08-04 | 2000-01-16 | Esteve Labor Dr | Procedimiento para la obtencion de los enantiomeros de cizolirtina. |
ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
ATE306481T1 (de) * | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
NZ516553A (en) | 1999-06-16 | 2004-01-30 | Univ Temple | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 and its preparation method |
DK1268435T3 (da) * | 2000-03-23 | 2007-03-12 | Solvay Pharm Bv | 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk aktivitet |
EP1299374B1 (en) * | 2000-06-22 | 2006-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
WO2002010135A1 (fr) * | 2000-08-01 | 2002-02-07 | Ono Pharmaceutical Co., Ltd. | Composes derives de 3,4-dihydroisoquinoline et medicaments contenant ces composes comme principe actif |
ES2174757B1 (es) | 2001-04-06 | 2003-11-01 | Esteve Labor Dr | Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. |
ES2180449B1 (es) * | 2001-07-06 | 2004-01-16 | Esteve Labor Dr | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria. |
AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
DE60215960T2 (de) * | 2001-09-21 | 2007-03-01 | Solvay Pharmaceuticals B.V. | Neue 4,5-dihydro-1h-pyrazol-derivate mit cb1-antagonistischer wirkung |
CA2442245C (en) * | 2001-09-21 | 2010-03-30 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
TW200302726A (en) * | 2002-01-31 | 2003-08-16 | Ono Pharmaceutical Co | Nitrogen-containing bicyclic compound and medicament containing same as active ingredient |
US20050137251A1 (en) * | 2002-03-18 | 2005-06-23 | Aaron Garzon | Dexanabinol and dexanabinol analogs regulate inflammation related genes |
EP1539754A4 (en) * | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
SE0300010D0 (sv) * | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
WO2004078261A1 (en) | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
EP1651612B9 (en) * | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
US7745476B2 (en) * | 2004-01-30 | 2010-06-29 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
ES2311972T3 (es) * | 2004-01-30 | 2009-02-16 | Solvay Pharmaceuticals B.V. | Derivados 1,3,5-trisubstituidos de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1. |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
ITMI20041033A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
WO2006044556A2 (en) * | 2004-10-14 | 2006-04-27 | Galileo Pharmaceuticals, Inc. | Dual inhibitors of lipoxygenase for treating diabetes |
RU2007119315A (ru) * | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
AR052660A1 (es) | 2005-01-21 | 2007-03-28 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir la cdk's y gsk's |
JP2008528469A (ja) | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007009720A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve S.A. | Prodrugs of pyrazoline compounds, their preparation and use as medicaments |
-
2005
- 2005-07-15 EP EP05384029A patent/EP1743890A1/en not_active Withdrawn
-
2006
- 2006-07-14 TW TW095125888A patent/TW200738699A/zh unknown
- 2006-07-14 US US11/457,720 patent/US20070073056A1/en not_active Abandoned
- 2006-07-14 PE PE2006000847A patent/PE20070194A1/es not_active Application Discontinuation
- 2006-07-15 CN CNA2006800333855A patent/CN101263120A/zh active Pending
- 2006-07-15 KR KR1020087002951A patent/KR20080032157A/ko not_active Application Discontinuation
- 2006-07-15 BR BRPI0613057-7A patent/BRPI0613057A2/pt not_active IP Right Cessation
- 2006-07-15 AU AU2006271994A patent/AU2006271994A1/en not_active Abandoned
- 2006-07-15 JP JP2008520810A patent/JP2009501181A/ja active Pending
- 2006-07-15 CA CA002612468A patent/CA2612468A1/en not_active Abandoned
- 2006-07-15 WO PCT/EP2006/006963 patent/WO2007009689A1/en active Application Filing
- 2006-07-15 EP EP06776261A patent/EP1917247A1/en not_active Withdrawn
- 2006-07-15 RU RU2008105761/04A patent/RU2008105761A/ru not_active Application Discontinuation
- 2006-07-15 MX MX2008000736A patent/MX2008000736A/es not_active Application Discontinuation
- 2006-07-17 CA CA002611366A patent/CA2611366A1/en not_active Abandoned
- 2006-07-17 CN CNA2006800250373A patent/CN101248063A/zh active Pending
- 2006-07-17 US US11/995,755 patent/US20090054509A1/en not_active Abandoned
- 2006-07-17 EP EP06762650A patent/EP1910339A2/en not_active Withdrawn
- 2006-07-17 JP JP2008520812A patent/JP2009501182A/ja not_active Withdrawn
- 2006-07-17 WO PCT/EP2006/007012 patent/WO2007009722A1/en active Application Filing
- 2006-07-17 US US11/995,775 patent/US7994200B2/en not_active Expired - Fee Related
- 2006-07-17 EP EP06762649A patent/EP1937668A1/en not_active Withdrawn
- 2006-07-17 JP JP2008520813A patent/JP2009501183A/ja not_active Withdrawn
- 2006-07-17 CN CNA2006800250439A patent/CN101238117A/zh active Pending
- 2006-07-17 EP EP06762648A patent/EP1910344A2/en not_active Withdrawn
- 2006-07-17 MX MX2008000737A patent/MX2008000737A/es not_active Application Discontinuation
- 2006-07-17 EP EP06762651A patent/EP1910301A2/en not_active Withdrawn
- 2006-07-17 US US11/995,766 patent/US8106085B2/en not_active Expired - Fee Related
- 2006-07-17 CA CA002611364A patent/CA2611364A1/en not_active Abandoned
- 2006-07-17 WO PCT/EP2006/007011 patent/WO2007009721A2/en active Application Filing
- 2006-07-17 US US11/995,750 patent/US20080269201A1/en not_active Abandoned
- 2006-07-17 WO PCT/EP2006/007014 patent/WO2007009724A2/en active Application Filing
- 2006-07-17 WO PCT/EP2006/007013 patent/WO2007009723A2/en active Application Filing
- 2006-07-17 MX MX2008000738A patent/MX2008000738A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070194A1 (es) | Compuestos de pirazolina 4-sustituidos como moduladores de cb1 | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
NO20084350L (no) | Heterocykliske amider til anvendelse som farmasoytika | |
PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
PE20150463A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORgamma | |
DE602005014086D1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
EA200870521A1 (ru) | Замещенные спироциклические антагонисты cgrp-рецепторов | |
EP1804919A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
BRPI0916235A8 (pt) | Composto, composição farmacêutica, e, uso do composto ou da composição | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20091093A1 (es) | Compuesto heterociclico que contiene nitrogeno y su uso | |
NO20072435L (no) | CGRP-reseptorantagonister | |
PE20161206A1 (es) | Derivado de urea o sal farmacologicamente aceptable del mismo | |
DK1778677T3 (da) | Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler | |
ATE494277T1 (de) | 3, 5-disubstituierte phenyl-piperidine als modulatoren der dopamin- neurotransmission | |
MA31889B1 (fr) | N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci | |
MX2010001080A (es) | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. | |
MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
RS52594B (en) | NON-STEROID ANTAGONISTS OF MINERALOCORTICOID RECEPTORS OBTAINED FROM 6H-DIBENZO [B, E] OXPINE | |
TW200745039A (en) | Isotopically substituted pantoprazole | |
PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
ES2421896T3 (es) | Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |